Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Alison E., Chan, Stacia, Wang, Zhiyong, McCloskey, Asako, Reilly, Quinn, Wang, Jayden Z., Patel, Hetika Vora, Koshizuka, Keiichi, Soifer, Harris S., Kessler, Linda, Dayoub, Ashley, Villaflor, Victoria, Adkins, Douglas R., Bruce, Justine Y., Ho, Alan L., Perez, Cesar A., Hanna, Glenn J., Gascó Hernández, Amaya, Saunders, Andrew, Dale, Stephen, Gutkind, J. Silvio, Burrows, Francis, Malik, Shivani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543974/
https://www.ncbi.nlm.nih.gov/pubmed/37339176
http://dx.doi.org/10.1158/0008-5472.CAN-23-0282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543974/
https://www.ncbi.nlm.nih.gov/pubmed/37339176
http://dx.doi.org/10.1158/0008-5472.CAN-23-0282

Ejemplares similares